OCAT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCAT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ocata Therapeutics's Long-Term Debt for the quarter that ended in Sep. 2015 was $5.69 Mil.
Ocata Therapeutics's quarterly Long-Term Debt stayed the same from Mar. 2015 ($0.00 Mil) to Jun. 2015 ($0.00 Mil) but then increased from Jun. 2015 ($0.00 Mil) to Sep. 2015 ($5.69 Mil).
Ocata Therapeutics's annual Long-Term Debt declined from Dec. 2012 ($3.17 Mil) to Dec. 2013 ($1.16 Mil) and declined from Dec. 2013 ($1.16 Mil) to Dec. 2014 ($0.00 Mil).
The historical data trend for Ocata Therapeutics's Long-Term Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocata Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec05 | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | |||||||||||
Long-Term Debt | Get a 7-Day Free Trial | - | 0.13 | 3.17 | 1.16 | - |
Ocata Therapeutics Quarterly Data | ||||||||||||||||||||
Dec10 | Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | |
Long-Term Debt | Get a 7-Day Free Trial | - | - | - | - | 5.69 |
Ocata Therapeutics (NAS:OCAT) Long-Term Debt Explanation
Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.
Thank you for viewing the detailed overview of Ocata Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Levy | director | |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Edward H Myles | officer: COO & CFO | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Paul K Wotton | director, officer: President and CEO | C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341 |
Jooste H Le Roux | officer: SVP of Bus Development & CCO | C/O NABI BIOPHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487 |
Gregory D Perry | director | C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451 |
Robert Langer | director | 98 MONTVALE RD, NEWTON MA 02459 |
Michael D West | director | AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501 |
Pedro Huertas | officer: Chief Development Officer | 950 WINTER STREET, NORTH, WALTHAM MA 02451 |
Alan G Walton | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 385 E. COLORADO BLVD., SUITE 299, PASADENA CA 91101 |
Robert Peabody | director, officer: VP - Grant Administration | ONE INNOVATION DRIVE, WORCHESTER MA 01605 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.